This CPB has been revised to remove the following criteria requirements for eptinezumab-jjmr (Vyepti): (i) 8-week trial requirement with other medications indicated for migraine prevention; and (ii) requested drug not be used concurrently with another calcitonin gene-related peptide (CGRP) receptor antagonist.